Document:

Exhibit 10.22

 

Agreement for work

 

on

 

pharmaceutical advertising

 

between

 

MKM Co-Pharma GmbH

(a company of the MKM group)

Commercial Registry Number (HRB) 137100

represented by the directors

Dr. Susan Rackwitz

Dr. Helga Vogt

Fleck 34 – 36

83661 Lenggries

Germany

 

- hereinafter referred to as “MKM”
-

 

and

 

CorMedix Inc.

represented by

Randy Milby

Art Morelli

745 Route 202-206, Suite 303

Bridgewater, NJ 08807

USA

 

- hereinafter referred to as the “Client”
-

 

Preamble

 

The Client is a pharmaceutical company
that develops and seeks to commercialize therapeutic products for the treatment of cardiac and renal dysfunction and is interested
as such in advertising their product(s) with the help of MKM, an experienced service company specialised in pharmaceutical advertising.

 

Subject Matter of the Agreement

 

		1.1	MKM shall implement the effective advertising measures agreed upon between the parties within the
framework of the provisions shown below in the territory mentioned under clause 3.1 or agreed between upon the parties (contract
territory) for the product mentioned under clause 2 of this agreement (contract product). For these purposes, MKM shall deploy
a national sales manager, who is solely subject to the instructions given on the part of MKM. MKM shall owe the success of the
advertising of the contract products, such as those described in clause 1.2.

 

    	 

    	 

    

 

Sheet
2/ Agreement for work on Pharmaceutical advertising /Cormedix Inc. 

 

		1.2	The advertising tasks to be performed by MKM are as follows:

 

		o	Visit of medical specialists (doctors) in dialysis medicine and nursing staff, working in dialysis
centres, established within the contract territory according to the list of dialysis centres / doctors of the Client in accordance
with the instructions of the Client for the purposes of the most effective advertising of the contract product

 

		o	Information of the doctors about the contract product

 

		o	Handing-over of promotional material and medical samples

 

		o	Encouragement of doctors to recommend or to prescribe the contract product in the future

 

		o	According to the regularly updated and mutually agreed upon Work Plan

 

		1.3	The start of activity of MKM is the start of the national sales manager ́s work (Pre marketing
/ contact / Networking / Targeting), which is 2nd January, 2013. The results of the national sales manager ́s work
will determine the size of a subsequently installed sales force, the sales force areas and the sales force start. The mentioned
topics have to be agreed between the parties in February 2013, the sales force start date is estimated at 1st of March
2013 and regulated in a separate contract.

 

		1.4	MKM shall commit itself to exclusively employ the national sales manager for the performance of
the advertising tasks described above who has – at latest after the product training of the Client - the necessary technical
knowledge in accordance with § 31 MPG (German Law concerning medical products). The national sales manager regards the obligations
in accordance with § 31 MPG (Communication of side effects etc.). The national sales manager employed by MKM shall be exclusively
subject to the instructions of MKM and shall be obliged to provide activity reports to MKM only. All activity reports are supplied
to the Client.

 

Any integration of the national
sales manager into the management organisation of the Client shall not take place. In the event that the Client considers the advertising
success in accordance with clause 1.1 to be jeopardised due to the unsatisfactory operational performance of the national sales
manager employed by MKM, they shall inform MKM in writing about their concrete complaints without delay.

 

MKM shall take the necessary
disciplinary actions and shall assure that the complaint is remedied within a period of four weeks following information. In the
event that the complaint is not remedied within a period of four weeks, the Client shall be authorised to require the national
sales manager be replaced by a substitute with equivalent or superior credentials if available. If an equal or superior substitute
is unavailable, the agreement remains dormant until an adequate replacement can be found.

 

		1.5	MKM agrees the national sales manager, Mr. Petrak may take a Co-Managing Directorship if the Client
decides to create such a position within CorMedix GmbH. This offer made at 

 

    	2/9

    	 

    

 

Sheet
3/ Agreement for work on Pharmaceutical advertising /Cormedix Inc. 

 

CorMedix Inc. discretion. All related increased costs
need to be agreed between both parties in writing.

 

2.Contract Products

 

		2.1	The successes presented in clause 1 of this agreement shall be owed by MKM with regard to the product
listed below:

 

Neutrolin®

 

		2.2	MKM shall agree to integrate any further products of the Client into the advertising activity.
In the event that the advertising activities of MKM should also extend to any further products of the Client, then this shall require
the conclusion of an appropriate agreement between the parties.

 

3.Contract Territory

 

		3.1	The advertising measures resulting from clause 1 and clause 2 of this agreement are to be implemented
by MKM within parts of the geographic territory of the Federal Republic of Germany.

 

The advertising success shall
be owed in parts of the designated territory in a country-wide manner as far as possible, which means that MKM shall ensure within
the framework of what is possible and reasonable that as many potentially interested customers as possible are satisfied with the
advertising measures.

 

		3.2	The territory shall be occupied by MKM with one national sales manager.

 

		3.3	Any services which are commissioned in the form of special measures other than during the visits
to the doctors (e.g. mailing activities) shall be the subject of a special agreement and shall be separately charged.

 

4.Remuneration

 

As regards the performance of
the tasks assumed, the Client shall pay MKM a remuneration which shall be calculated in accordance with the below provisions.

 

		4.1	The following rate of remuneration shall be agreed upon for the first twelve months of cooperation:

 

Per national sales manager working
day, MKM charge a daily fee in the amount of € 680.00 plus VAT.

 

The following shall be deemed
to be a working day:

 

		o	Days spent in the field service

 

		o	Instructional days (if approved by the Client)

 

    	3/9

    	 

    

 

Sheet
4/ Agreement for work on Pharmaceutical advertising /Cormedix Inc. 

 

		o	Congress days (if approved by the Client)

 

		o	Training days (if approved by the Client)

 

		o	Education days (if approved by the Client)

 

		o	Office days (if approved by the Client)

 

		o	Self-study days (if approved by the Client)

 

The rates of remuneration shall
also be due on weekends and on bank holidays, e.g. on the occasion of congresses, conferences, training measures, etc.

 

The following costs are included
in the remuneration rate:

 

		o	Selection of the national sales manager

 

		o	Employee salary of the national sales manager (twelve times per year)

 

		o	Paid holidays (2.5 working days per month)

 

		o	Statutory rules on continued payment in the event of sickness

 

		o	Tax-free compensation to employees for capital accumulation purposes (€ 27.00/month) from
the 7th month of company service

 

		o	The entire vehicle costs up to a monthly kilometre allowance of 4,000 service kilometres for the
national sales manager (to be itemized with travel expenses)

 

		o	Employer’s contribution regarding social security

 

		o	24-hour accident insurance

 

		o	Per diem expenses in accordance with legal provisions

 

		o	Telephone costs of the national sales manager

 

		o	Installation of an ISDN/DSL connection up to € 50 gross

 

		o	Monthly costs for a DSL connection up to a maximum of € 17 gross

 

		o	Postal charges

 

The rate of remuneration shall
be calculated as full or half daily rates. In the event of sickness or holiday of the national sales manager the payments for this
person shall not be applicable.

 

The following shall not be included
in the remuneration rate and shall thus be separately charged and itemized provided however that all hotel and travel costs must
be in compliance with the client`s travel policies as established from time to time to be reimbursed:

 

    	4/9

    	 

    

 

Sheet
5/ Agreement for work on Pharmaceutical advertising /Cormedix Inc. 

  

		o	The hotel costs incurred within the framework of the presentation of potential candidates at the
Client

 

		o	Hotel costs in the event of necessary overnight stays, e.g. during product training and within
the framework of the field service activities to be rendered (e.g. in seminars, congresses, etc.) – lodging approved by Client

 

		o	Travel costs of the national sales manager approved by the Client, to be invoiced separately, e.g.
for product and sales training, for conferences, etc. (train and/or flight ticket – 2nd class)

 

		o	Extraordinary expenditure regarding customer care approved by the Client

 

		o	Service kilometres exceeding a monthly kilometre allowance as approved by the Client of more than
4,000 km per national sales manager, which can be charged separately by MKM in the amount of € 0.41/km

 

		o	Extraordinary expenditure, e.g. for specialist books, info and sales material approved by the Client

 

		o	Other extra costs approved by the Client

 

		o	Bonus payments plus employer’s contribution for social security (bonus system)

 

		o	Days off assigned and approved by the Client

 

As regards the utilisation of
the “PROSA” reporting system owned by MKM is for the Client free of charge. Any possibly-incurring adaptation costs
for the reporting systems should still be discussed if required. MKM have their own permanent team, which is able to quickly implement
any necessary changes to the MKM reporting system.

 

		4.2	At the beginning of this month, MKM shall issue to the Client a provisional invoice for the ongoing
month. The Client shall settle the invoice by the 15th day of this month at the latest, without deducting any discount.
Together with the provisional invoice for the following month, MKM shall account the completed month by taking the final itemized
invoice items as a basis. Any difference amounts shall be balanced with the provisional invoice for the following month. The Client
will install an German account in trust for this matter.

 

5.Obligations of MKM

 

		5.1	MKM shall commit themselves to generate the owed advertising effect in accordance with the contractually
agreed-upon specifications and instructions of the Client with the due diligence of a prudent businessman. MKM shall, in particular,
protect the interests of the Client and shall represent the Client and the Client’s products vis-à-vis any third parties
in proper and due form. 

 

MKM shall be obliged to provide
evidence to the Client of visits to doctors by territory and by number. The evidence shall be provided by means of the MKM sales
force management

 

    	5/9

    	 

    

 

Sheet
6/ Agreement for work on Pharmaceutical advertising /Cormedix Inc. 

 

 system, from which relevant data shall be transferred to the Client. The Client shall accept this as evidence
of the success owed by MKM.

 

		5.2	MKM will inform the Client about co-promotion possibilities as they arrive. If the Client approves
such co-promotion, the framework and conditions have to be mutually agreed upon in writing and amended to this agreement.

 

6.Obligations of the Client

 

		6.1	The Client shall make available to MKM any and all information and documents necessary for the
implementation of advertising measures, in particular product information, examples, product samples, etc., in sufficient quantities
and free of charge.

 

		6.2	The Client shall be further obliged to train the national sales manager employed by MKM free of
charge and in a proper manner for advertising the contract products (product training). Within the framework of this training,
any and all information required for the implementation of the product advertising are to be submitted to the national sales manager.

 

		6.3	During the first 12 months of the term of this agreement, the Client shall commit themselves not
to directly hire the MKM national sales manager away from MKM, neither as freelance worker nor as employee unless the Client pays
MKM a fee equal to (a) € 11.900 plus VAT multiplied by (b) 12 minus the number of contract months elapsed (a “Direct
Hire”). The same shall also apply to any other companies which are part of the group of the Client.

 

7.Confidentiality

 

MKM shall commit themselves
to maintain confidentiality about any and all operational circumstances and processes concerning the Client. The same shall also
apply to any product-related information, provided that they are not to be used for any advertising purposes within the framework
of the functions assumed and have been explicitly designated in writing by the Client as being confidential. MKM shall ensure that
an appropriate obligation to secrecy will also agreed upon by contract together with the national sales manager / qualified medical
product consultant / sales representative working for them. The aforementioned obligations shall also continue to apply following
the termination of the agreement.

 

8.Liability

 

		8.1	MKM shall execute the advertising order given to them with the due diligence of a prudent businessman.
MKM shall not be responsible for the effect or the economic success of the promotional measures implemented.

 

		8.2	MKM shall only be obliged to offer compensation for any damage resulting from the delayed beginning
or the interruption of the advertising measures as well as from the withdrawal of the order in the event that the delay, the interruption
or the withdrawal of the order has been caused by a wrongful act or gross negligence.

 

    	6/9

    	 

    

 

Sheet
7/ Agreement for work on Pharmaceutical advertising /Cormedix Inc. 

 

9.Reporting Obligations of MKM

 

		9.1	MKM shall inform the Client electronically at agreed-upon time intervals and in the agreed scope
about the ways and modalities by means of which the advertising measures commissioned are implemented, especially about the number
of the visits made to the doctors and the advertising material handed over.

 

In this context, MKM shall also
provide information to the Client about their insights regarding the effect of the advertising measures implemented and, in particular,
about any relevant insights regarding the acceptance of the contract product as regards the addressed relevant public.

 

		9.2	MKM shall be obliged to notify the Client in writing about any possible side effects and contraindications
which have become known in connection with the advertising of the products listed under clause 2 without delay.

 

10.Duration of the Advertising Measures
and Termination of this Agreement

 

The advertising activities taken
over by MKM are to be implemented in the territory and at the points in time agreed between the parties.

 

This agreement shall come into
effect when signed by both contracting parties, and its fixed term shall run from 1st of January 2013 until the expiry of 12 months
following the beginning of the agreement, this means until 31th of December 2013.

 

Both parties shall only have
the right to any premature termination of the agreement for good cause. A good cause for the Client to terminate the agreement
shall be deemed to exist in the event that, for example, the advertising activity according to the agreement has not been started
within four weeks (at the latest) of the beginning of the agreement, in accordance with clause 1.2 of this agreement or a Direct
Hire has occurred.

 

The parties shall continue to
have an extraordinary right entitling them to terminate the agreement without notice in the event that

 

		-	one of the contracting parties grossly breaks its contractual duties and does not remedy this breach
of duty upon a written warning (registered letter) on the part of the other contracting party within a period of four weeks;

 

		-	one of the contracting parties is in liquidation or an application of insolvency proceedings regarding
their assets has been filed.

 

If one of these situations occurs
on the part of the Client and if MKM or the Client terminate the agreement, then the Client shall be obliged to compensate MKM
for the remuneration paid to the national sales manager in accordance with clause 4.1 of the present agreement until the next permissible
date of termination of his employment contract concluded with MKM, provided however the payment obligation by Client shall not
exceed three months, beginning with the first day of the month following the notice of cancellation.

 

    	7/9

    	 

    

 

Sheet
8/ Agreement for work on Pharmaceutical advertising /Cormedix Inc. 

 

Any terminations are to be made
in writing.

 

Upon termination of the agreement,
MKM shall return the documents made available to them to the Client, provided that the documents have not been used up in the course
of the implementation of the advertising measures.

 

11.Miscellaneous

 

In the event that any of these
clauses should be or become inapplicable or incomplete, then this shall not affect the effectiveness of the remaining provisions.
In lieu of the invalid provisions, an admissible provision which comes as closest as possible to the economic purpose of the invalid
provision shall be deemed to have been agreed upon retroactively. The same shall apply in the event that the agreement turns out
to be incomplete.

 

Any additions or amendments
to this agreement shall only be valid if made in writing and signed by both parties; the same shall also apply to any agreement
which waives this clause which requires the written form.

 

The parties shall endeavour
to amicably settle any differences resulting from or in connection with this agreement. In the event that a mutual agreement should
not be possible, then the place of jurisdiction for this dispute shall be deemed to be Munich, Germany.

 

Unless otherwise specified above,
the regulations of German law, particularly the German Civil Code (Bürgerliches Gesetzbuch) shall prevail over the
agreement for work, §§ 631 etc. seqq.

 

	Lenggries, den	10th January 2013	 	Bridgewater, den	 	 
	/s/ Dr. rer. nat. Helga Vogt	 	 
	CHRO / HR & Admin	 	 
	 	 	 
	and	 	/s/ Randy Milby
	 	 	Randy Milby
	/s/ Esther Heil-Kottmair	 	CEO
	Legal Assessor / Authorized Signatory	 	Date 1-8-2013
	 	 	 
	MKM Co-Pharma GmbH	 	CorMedix Inc.	 

 

    	8/9

    	 

    

 

Appendix I

 

Engagement Work Plan

 

Work Plan divided into three phases:

 

Phase 1) Jan/ Feb/March – Market Review
and Planning,

Phase 2) April/May – Neutrolin Launch
and Sales Ramp-up

Phase 3) June and beyond – Growth
and Expansion

 

Phase 1) Market Review and Planning

 

A) Visit on average three Hemodialysis (HD) centers each week
which are selected based on MKM and Herr Petrak’s experience/knowledge and other information data sets available

 

B) Conduct an assessment at each HD center. Key assessment metrics
below include but are not limited to:

 

a) appreciation for the impact of CVC thrombosis and
CRBSIs on patients and the German healthcare system

 

b) knowledge of biofilms and their significance to
HD center and German healthcare system

 

c) validate or disprove the 20% CVC use assumption

 

d) Product (s) used/available and rationale for use

 

e) Competitive product costs/ decision makers and
process for adding new products

 

f) reaction/intent to use based a blinded TPP for
Neutrolin versus current practice

 

g) knowledge of literature in  the CVC thrombosis,
CRBSI space

 

h) reaction to a CRMD reprint

 

i) knowledge of the cost of these complications

 

j) competitive company activities in the space

 

C) February and March activities shall include above as well
as

 

 a) test sales/marketing materials

 

b) develop advocates and KOLs

 

c) identifying early adopter
physicians and HD centers

 

    	9/9

    	 

    

 

d) negotiate wholesaler relationships
for initial orders

 

e) plan and identify members
for client Advisory Board

 

 f) identify initial and expansion sales territories

 

 g) assist Client with a review of sales training materials and programs

 

D) File the following reports:

 

1) bi-weekly written report summarizing
activities and key learnings

 

2) monthly personal summary report to Client
management

 

E) Client (at client’s discretion)
to accompany Herr Petrak to pre-identified HD centers during last weeks of January and February 2013

 

At completion of Phase 1 deliver a situational
analysis of the market with detailed information of size, structures, key customers, competition analysis and a strategic and operational
market capture plan, including a 2-3 year sales projection serving as a baseline for Phase 2 Neutrolin Launch and Sales Ramp up.

 

Phase 2 Neutrolin Launch and Sales Ramp-up,
Herr Petrak will

 

A) With Client will develop a “bottom-up” unit and
revenue monthly sales forecast by territory and aggregate for the contracted product for 2013 and 2014 derived from information
obtained in Phase 1. Client will have final approval of forecast.

 

B) Generate sales to his best efforts as per monthly forecast

 

C) Supervise sales representatives and direct sales representative
activities.

 

D) Conduct marketing and sales activities as directed by Client

 

E) Provide to Client quarterly assessments of sales representative
performance.

 

Phase 3 Neutrolin Sales Growth and Expansion, Herr Petrak
will

 

		A)	Held develop and execute Neutrolin growth and expansion marketing and sales plan

		B)	Generate sales to his best efforts as per monthly forecast

 

    	 

    	 

    

 

Appendix 1 Agreement for Work on
Pharmaceutical Advertising

 

	Distriktnumber	District
	National Sales Manager	Parts of Germany agreed between the PartiesEXHIBIT 10.1

 

TERMINATION
AGREEMENT

 

 

This Agreement
is made as of this 29th day of October, 2012, by and between China YCT International Group, Inc. a Delaware corporation with its
principal place of business at Gucheng Road, Sishui County, Shandong Province, China 273200 (”CYIG”), LY Research Corp.,
a New Jersey corporation, with its registered office at 22 Sunrise Bay Boulevard, Tuckerton, New Jersey 08087 (“LY Research”),
LY. (HK) Biotech Limited, a Hong Kong corporation (“LYHK”) and LY Holding Limited, a New Jersey corporation (“Holding”,
LY Research, LYHK and Holding are collectively known as “LY”) and McLaughlin & Stern LLP, 260 Madison Avenue, New
York New York 10016 (“Escrow Agent”).

 

WHEREAS, the parties executed a
Purchase Agreement in February 2011, as amended as of August 15, 2011 and October 21, 2011 (the “Purchase Agreement”)
which provided, in part, for the transfer to CYIG of US patent No. 6,475,531 B1 (the “Patent””) in consideration
for the issuance of shares of common stock of CYIG

 

WHEREAS, LYHK assigned the Patent
to CYIG on January 25, 2011 (the “Assignment”), and CYIG issued 44,255,067 shares of Common Stock (the “Shares”)
to Holding in consideration for the Patent and agreed to issue additional shares of Common Stock to Holding upon the satisfaction
of certain conditions;

 

WHEREAS, the Purchase Agreement
provides that if certain conditions are not fulfilled on or before October 21, 2012, the Patent will be returned to LYHK and the
Shares will be returned to CYIG;

 

WHEREAS, such conditions have not
been fulfilled and the parties desire to return the Patent and the Shares and to terminate the Purchase Agreement.

 

NOW, THEREFORE, the parties agree
as follows:

 

1.       Delivery of Documents.

 

i.       LY shall deliver
the following documents to Escrow Agent:

a.       stock certificate 7077 of CYIG
for the Shares (“Stock Certificate”),

b.       stock power duly executed by
an officer of Holding, with a medallion guaranteed signature in the form attached as Exhibit A (“Stock Power”),

c.       assignment agreement between
CYIG and LY, substantially in the form attached as Exhibit B, duly executed by LY and providing for the assignment of the Patent
from CYIG to LYHK (the “Assignment Agreement”),

d.
      letter from Holdings addressed to the transfer agent of CYIG to cancel the shares in the
form attached as Exhibit C (“Holding Letter”), and

e.       certification
of resolutions of the Board of Directors of Holding authorizing Yaguang Liu to execute the stock power on behalf of Holdings
in the form of Exhibit D (“Certification”).

 

ii.       CYIG shall
deliver the following documents to Escrow Agent:

a.
      Assignment Agreement, duly executed by CYIG,

b.       Recording of
Assignment, duly executed by CYIG, in the form attached as Exhibit E (“Assignment Recording”), and

 

    	1

    	 

    
 

c.       Recording form
cover sheet, duly executed by CYIG, in the form attached as Exhibit F (“Cover Sheet”).

 

2.       Release of Documents.
      Upon receipt of the documents as provided in Section 1 (the “Documents’), the Escrow Agent is authorized to release
the Documents listed in Section 1(i) (the Stock Certificate, Stock Power, Holding Letter, Certification and Assignment Agreement
to CYIG) and the Documents listed in Section 1(ii) (the Assignment Agreement, Assignment Recording and the Cover Sheet) to LY.

 

3.       Escrow Agent. 

 

i.       The Escrow
Agent shall have no duties or obligations other than as stated in this agreement and shall be protected in acting upon any
affidavit, notice, document or other communication from the LY or the CYIG (or their respective counsel, employees or
agents), which the Escrow Agent, in good faith, believes to be valid or genuine and to have been signed and presented by the
LY or CYIG (or their respective counsel, employees or agents).

 

ii.       The Escrow
Agent shall have no liability whatsoever arising from any of its actions or omissions hereunder except for willful misconduct or
gross negligence. The CYIG and LY jointly and severally agree to indemnify the Escrow Agent against any and all costs, expenses,
fees (including attorneys' fees) and charges incurred in connection with this Agreement.

 

iii.       Should any
controversy arise among the parties hereto with respect to this Agreement, the Escrow Agent shall have the right to consult counsel
and/or to institute an appropriate interpleader action to determine the rights of the parties.

 

iv.       The Escrow Agent
may act in reliance upon any instrument or signature believed by it in good faith to be genuine and may assume that any person
purporting to give receipt or advice or make any statement or execute any document in connection with the provisions hereof has
been duly authorized to do so.

 

4.       Termination.
      Upon the release of the Documents from escrow and the recording of the assignment of the Patent with the United States Patent
and Trademark Office, the Purchase Agreement and any and all of the respective rights, benefits, and obligations of CYIG and LY
existing or arising under, pursuant to or in connection with the Purchase Agreement are hereby cancelled and rendered null and
void in their entirety subject to and upon the terms and conditions set forth herein.

 

5.       Release       Upon the release
of the Documents and by reason of the Termination Agreement, the parties expressly acknowledge, agree, and stipulate as follows:

 

i.       No party owes any
sums to any other party under, or pursuant to the Purchase Agreement or otherwise. No party has any claim or cause of action against
the other arising out of, pursuant to, or in connection with, the Purchase Agreement through and as of the date hereof;

 

ii.       The express purpose
of the Termination Agreement is to effect a complete, final, and unconditional settlement between the parties with respect to the
Purchase Agreement and any and all matters, transaction, or disputes between the parties thereunder or otherwise which may be outstanding
through and as of the date hereof; and

 

    	2

    	 

    
 

iii.       Upon the
cancellation and termination of the Purchase Agreement effected by the provisions hereof, no party shall have any remaining
duties or obligations whatsoever to the other with respect to any matter or transaction except that the parties agree to
execute any additional documents as may be reasonably required to effectuate the purposes of this Agreement.

 

6.       Representations.

 

i.       LY represents and warrants
to CYIG that LY is the sole beneficial owner of the Shares, and owns the Shares, free and clear of all mortgages, pledges, restrictions,
liens, charges, encumbrances, security interests, obligations or other claims.

 

ii.       CYIG represents and warrants to LY that
CYIG is the sole beneficial owner of the Patent, and owns the Patent, free and clear of all mortgages, pledges, restrictions, liens,
charges, encumbrances, security interests, obligations or other claims.

 

7.
      Entire Agreement.       This Termination Agreement constitutes the entire agreement of
the parties hereto with respect to the matters herein contained and may not be altered, modified, or amended except in
writing, executed, and delivered by or on behalf of the parties.

 

8.       Notice.
      All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have
been duly given (a) on the date of receipt if delivered personally or by overnight courier, (b) on the day of transmission if
sent by facsimile/email transmission and confirmation of receipt is obtained, or (c) on the fifth day after mailing,
registered or certified, postage prepaid return receipt requested, to the parties at the address first set forth above, with
the notices to LY to be sent to LY Research.

 

9.       Miscellaneous.
      This Agreement may not be changed, modified or amended except by writing signed by both parties hereto. This Agreement shall be
binding upon and inure to the benefit of the successors, affiliates and assigns of the parties. This Agreement shall be governed
by the laws of the State of New York without regard to conflicts of laws. In the event of conflict, the parties consent to the
jurisdiction and venue of the courts of the State of New York.

 

    	3

    	 

    
 

IN WITNESS WHEREOF,
the parties have hereunto set their hands as of the date first written above.

 

 

 

	 	L. Y. Research Corporation
	 	 	 
	 	By:	/s/ Yaguang Liu          
	 	   	Yaguang Liu
	 	Title: 	Chief Executive Officer
	 	 	 
	 	 	 
	 	 	 
	 	L.Y. (HK) Biotech Limited
	 	 	 
	 	By:	/s/ Yaguang Liu          
	 	   	Yaguang Liu
	 	Title:	Chief Executive Officer
	 	 	 
	 	 	 
	 	 	 
	 	L.Y. HOLDING LIMITED
	 	 	 
	 	By:	/s/ Yaguang Liu          
	 	 	Yaguang Liu
	 	Title: 	Chief Executive Officer
	 	 	 
	 	 	 
	 	 	 
	 	China YCT International Group, Inc.
	 	 	 
	 	By:	/s/ Tinghe Yan            
	 	 	Tinghe Yan
	 	Title: 	Chief Executive Officer

 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}]]